Related Experiment Video
Updated: May 18, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Adoptive immunotherapy with Cl-IB-MECA-treated CD8+ T cells reduces melanoma growth in mice
Antonella Montinaro1, Giovanni Forte, Rosalinda Sorrentino
1Department of Pharmaceutical and Biomedical Sciences, University of Salerno, Salerno, Italy.
Abstract:
Cl-IB-MECA is a selective A3 adenosine receptor agonist, which plays a crucial role in limiting tumor progression. In mice, Cl-IB-MECA administration enhances the anti-tumor T cell-mediated response. However, little is known about the activity of Cl-IB-MECA on CD8+ T cells. The aim of this study was to investigate the effect of ex vivo Cl-IB-MECA treatment of CD8+ T cells, adoptively transferred in melanoma-bearing mice. Adoptive transfer of Cl-IB-MECA-treated CD8+ T cells or a single administration of Cl-IB-MECA (20 ng/mouse) inhibited tumor growth compared with the control group and significantly improved mouse survival. This was associated with the release of Th1-type cytokines and a greater influx of mature Langerin+ dendritic cells (LCs) into the tumor microenvironment. CD8+ T cells treated with Cl-IB-MECA released TNF-α which plays a critical role in the therapeutic efficacy of these cells when injected to mice. Indeed, neutralization of TNF-α by a specific monoclonal Ab significantly blocked the anti-tumor activity of Cl-IB-MECA-treated T cells. This was due to the reduction in levels of cytotoxic cytokines and the presence of fewer LCs. In conclusion, these studies reveal that ex vivo treatment with Cl-IB-MECA improves CD8+ T cell adoptive immunotherapy for melanoma in a TNF-α-dependent manner.
Insights
Cl-IB-MECA enhances CD8+ T cell immunotherapy for melanoma by boosting anti-tumor responses. This treatment improves survival through TNF-α release and increased dendritic cell infiltration into tumors.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- A3 adenosine receptor agonists, like Cl-IB-MECA, are known to limit tumor progression.
- Cl-IB-MECA enhances anti-tumor T cell responses in mice.
- The specific effects of Cl-IB-MECA on CD8+ T cells remain largely uncharacterized.
Purpose of the Study:
- To investigate the impact of ex vivo Cl-IB-MECA treatment on CD8+ T cells for adoptive immunotherapy in melanoma.
- To elucidate the mechanisms underlying Cl-IB-MECA's anti-tumor activity in a melanoma mouse model.
Main Methods:
- CD8+ T cells were treated ex vivo with Cl-IB-MECA and adoptively transferred into melanoma-bearing mice.
- Tumor growth, mouse survival, cytokine profiles, and dendritic cell infiltration were assessed.
- The role of TNF-α was evaluated using a specific monoclonal antibody for neutralization.
Main Results:
- Adoptive transfer of Cl-IB-MECA-treated CD8+ T cells significantly inhibited tumor growth and improved mouse survival.
- Treatment led to increased Th1-type cytokine release and greater infiltration of mature Langerin+ dendritic cells (LCs) into the tumor microenvironment.
- Neutralization of TNF-α abolished the anti-tumor effects, reducing cytotoxic cytokines and LC presence.
Conclusions:
- Ex vivo Cl-IB-MECA treatment enhances CD8+ T cell adoptive immunotherapy for melanoma.
- The therapeutic efficacy is mediated through TNF-α release by CD8+ T cells.
- This approach represents a promising strategy for melanoma treatment by modulating the tumor immune microenvironment.
